Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?

2.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al;

BMT CTN 1703 Investigators

.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.

doi:10.1056/NEJMoa2215943

.

3.

Broers

AEC

,

de Jong

CN

,

Bakunina

K

, et al.

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial

.

Blood Adv

.

2022

;

6

(

11

):

3378

-

3385

.

doi:10.1182/bloodadvances.2021005847

.

4.

Luznik

L

,

Pasquini

MC

,

Logan

B

, et al.

Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies

.

J Clin Oncol

.

2022

;

40

(

4

):

356

-

368

.

doi:10.1200/jco.21.02293

.

5.

Gooptu

M

,

Romee

R

,

St Martin

A

, et al.

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

.

Blood

.

2021

;

138

(

3

):

273

-

282

.

doi:10.1182/blood.2021011281

.

6.

Keating

AK

,

Langenhorst

J

,

Wagner

JE

, et al.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia

.

Blood Adv

.

2019

;

3

(

7

):

1118

-

1128

.

doi:10.1182/bloodadvances.2018025908

.

7.

Locatelli

F

,

Merli

P

,

Pagliara

D

, et al.

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion

.

Blood

.

2017

;

130

(

5

):

677

-

685

.

doi:10.1182/blood-2017-04-779769

.

8.

Klein

OR

,

Buddenbaum

J

,

Tucker

N

, et al.

Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies

.

Biol Blood Marrow Transplant

.

2017

;

23

(

2

):

325

-

332

.

doi:10.1016/j.bbmt.2016.11.016

.

9.

Trujillo

ÁM

,

Karduss

AJ

,

Suarez

G

, et al.

Haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source

.

Transplant Cell Ther

.

2021

;

27

(

5

):

427.e1

-

427.e7

.

doi:10.1016/j.jtct.2021.02.010

.

10.

Sharma

A

,

Rastogi

N

,

Chatterjee

G

,

Kapoor

R

,

Nivargi

S

,

Yadav

SP

.

Haploidentical stem cell transplantation with post-transplant cyclophosphamide for pediatric acute leukemia is safe and effective

.

J Pediatr Hematol Oncol

.

2021

;

43

(

7

):

e1033

-

e1036

.

doi:10.1097/MPH.0000000000002030

.

11.

Fierro-Pineda

JC

,

Tsai

HL

,

Blackford

AL

, et al.

Prospective PTCTC trial of myeloablative HaploBMT with post-transplant cyclophosphamide for pediatric acute leukemias

.

Blood Advance

.

2023

; bloodadvances.2023010281.

doi:10.1182/bloodadvances.2023010281

.

12.

Ruggeri

A

,

Galimard

J-E

,

Paina

O

, et al.

Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia

.

Transplant Cell Ther

.

2021

;

27

(

5

):

424.e1

-

424424.e9

.

doi:10.1016/j.jtct.2021.01.016

.

13.

Jurdi

NE

,

Hoover

A

,

O'Leary

D

, et al.

Phase II study of myeloablative 7-8/8-matched allotransplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil

.

Transplant Cellular Ther

.

2023

;

29

(

9

):

576.e1

-

576.e5

.

doi:10.1016/j.jtct.2023.06.008

.

14.

Symons

HJ

,

Zahurak

M

,

Cao

Y

, et al.

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

.

Blood Adv

.

2020

;

4

(

16

):

3913

-

3925

.

doi:10.1182/bloodadvances.2020001648

.

15.

Srinivasan

A

,

Raffa

E

,

Wall

DA

, et al.

Outcome of haploidentical peripheral blood allografts using post-transplantation cyclophosphamide compared to matched sibling and unrelated donor bone marrow allografts in pediatric patients with hematologic malignancies: a single-center analysis

.

Transplant Cell Ther

.

2022

;

28

(

3

):

158.e1

-

158158.e9

.

doi:10.1016/j.jtct.2021.11.009

.

16.

Hong

KT

,

Park

HJ

,

Kim

BK

,

An

HY

,

Choi

JY

,

Kang

HJ

.

Post-transplantation cyclophosphamide-based haploidentical versus matched unrelated donor peripheral blood hematopoietic stem cell transplantation using myeloablative targeted busulfan-based conditioning for pediatric acute leukemia

.

Transplant Cell Ther

.

2022

;

28

(

4

):

195.e1

-

195195.e7

.

doi:10.1016/j.jtct.2022.01.002

.

17.

Elmariah

H

,

Kasamon

YL

,

Zahurak

M

, et al.

Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first- degree related donors

.

Biol Blood Marrow Transplant

.

2018

;

24

(

5

):

1099

-

1102

.

doi:10.1016/j.bbmt.2018.02.005

.

18.

DeZern

AE

,

Franklin

C

,

Tsai

H-L

,

Varadhan

R

,

Imus

PH

,

Jones

RJ

.

The art of donor selection: donor age and relationship in NMA haplo BMT

.

Transplant Cell Ther

.

2021

;

27

(

3

):

s240

.

doi:10.1016/s2666-6367(21)00300-6

.